Submit Manuscript  

Article Details


Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas

Author(s):

Cécile Le Page*, Jacqueline Chung, Kurosh Rahimi, Martin Kobel, Diane Provencher and Anne-Marie Mes-Masson   Pages 1 - 22 ( 22 )

Abstract:


Aims: This review aims to present a summary of the new advances in search of biomarkers that have been recently undercovered and are entering clinical trials for patients with high grade or low grade serous epithelial ovarian cancer.

Background: Clinical parameters such as disease stage and residual disease, although helpful in the management of patients after their initial surgery, are not efficient enough to establish accurate prognostic and therapeutic strategies for serous epithelial ovarian cancer.

Objective: Present a summary of the most promising predictive biomarkers for high grade or low grade serous epithelial ovarian cancer.

Method: We reviewed pubmed for recent description of biomarkers in serous epithelial ovarian cancer. We focused on the most promising biomarkers that could impact therapeutic strategies.

Result: Efforts to identify monitoring and predictive factors have focused on molecular markers, genomic profiling and liquid biopsies. With increasing collaborative efforts of consortia to build multi-disciplinary teams and larger cohorts, the validation of biomarkers has significantly improved to address the heterogeneity of EOC and facilitate their introduction into clinical care. While BRCA testing is now a standard of care, promising biomarkers such as homologus recombination defect (HRD), immuno-markers (CD8, PD-1, PDL-1) are also entering clinical trials.

Conclusion:In the last decade, promising biomarkers have been validated and lead to new therapeutic strategies with PARP inhibitors, immunotherapy and anti-angiogenic agents. Biomarkers such as BRCA, homologus recombination defect (HRD), immuno-markers (CD8, PD-1, PDL-1), KRAS and PR, are now used in clinical trials.

Other: Assessment of genetic variants will soon represent the standard-of-care in gynecological cancers, not only to diagnose the disease but also to assist the prediction of clinical behavior of tumors and support personalized medicine to match patients with appropriate targeted therapies, improving treatment efficacy and quality of life for patients.

Keywords:

BRCA, markers, PARP inhibitors, immunotherapy, anti-angiogenic therapy, hormone therapy, long-term survival, targeted therapy, progression

Affiliation:

Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and Institut du cancer de Montréal, Montreal, QC, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and Institut du cancer de Montréal, Montreal, QC, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and Institut du cancer de Montréal, Montreal, QC, Department of Pathology, CHUM, Montreal, QC, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and Institut du cancer de Montréal, Montreal, QC, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and Institut du cancer de Montréal, Montreal, QC



Read Full-Text article